Disitamab vedotin shows phase 3 benefit in HER2-positive breast cancer liver metastases

Disitamab vedotin查看药品详情, an antibody–drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2 (搜索)搜索该靶点), significantly improves outcomes in patients with HER2-positive breast cancer (搜索)搜索该疾病 that has spread to the liver, according to phase 3 results from the RC48-C006 trial published in Nature Communications. The study, led by investigators including Wang, Ouyang and Xie, represents the culmination of a development program that has tracked the agent from early laboratory work through large-scale randomized testing in a patient population whose prognosis has historically remained grim despite decades of progress against HER2-driven disease.

Liver metastases (搜索)搜索该疾病 occupy a uniquely punishing position in the natural history of breast cancer. While modern HER2 (搜索)搜索该靶点-targeted therapies—starting with trastuzumab and extending through pertuzumab, lapatinib, tucatinib and trastuzumab deruxtecan查看药品详情—have transformed median survival for HER2-positive disease overall, patients whose cancer has seeded the liver have consistently fared worse than those with metastatic disease confined to other sites. The liver's dual blood supply, immunosuppressive microenvironment and frequent involvement in drug-resistant clones all contribute to poorer responses to systemic therapy, and the liver has long been regarded as a sanctuary-like site where conventional regimens lose much of their effectiveness.

Mechanism of Action

Disitamab vedotin查看药品详情, also known by its development code RC48, pairs a humanized anti-HER2 (搜索)搜索该靶点 antibody, disitamab, with monomethyl auristatin E (搜索)搜索该药品 (MMAE), a synthetic analog of molecules derived from marine shellfish toxins that disrupts microtubule assembly and drives apoptotic cell death during cell division. The antibody is conjugated to the payload through a valine-citrulline linker that is cleaved by cathepsin B, a protease enriched in lysosomes, releasing MMAE preferentially within HER2-expressing tumor cells.

The conjugation chemistry yields an average of approximately four MMAE molecules per antibody, achieved with a more homogeneous attachment strategy that reduces batch-to-batch variability. The antibody recognizes a distinct epitope on the extracellular domain of HER2 (搜索)搜索该靶点 compared with trastuzumab, which may allow the drug to bind tumor cells even when HER2 expression levels or conformations have shifted under the pressure of prior anti-HER2 treatment. A degree of bystander killing—release of membrane-permeable MMAE that diffuses to neighboring tumor cells regardless of their own HER2 density—adds a second layer of antitumor activity, considered particularly valuable in heterogeneous tumors where patches of low-HER2 cells can otherwise seed resistance.

Trial Design and Results

The RC48-C006 study was designed as a phase 2/3 program, with the pivotal phase 3 portion enrolling patients with HER2-positive breast cancer (搜索)搜索该疾病 and liver metastases (搜索)搜索该疾病 who had progressed on prior lines of systemic therapy. Participants were randomized to receive disitamab vedotin查看药品详情 or comparator chemotherapy, and the trial measured objective response rate and progression-free survival as its primary efficacy endpoints, alongside overall survival and safety.

In the reported results, patients treated with disitamab vedotin查看药品详情 achieved markedly higher response rates than those receiving standard chemotherapy, with a substantial fraction of tumors shrinking measurably on imaging. Progression-free survival was significantly extended, and early overall survival signals pointed in the same direction. The magnitude of benefit in a liver-dominant population—a setting in which even modern regimens often struggle—is the most consequential aspect of the data.

Safety Profile

Safety findings tracked the established profile of MMAE-based ADCs. The most commonly observed adverse events included reductions in white blood cell counts, peripheral sensory neuropathy manifested as numbness or tingling in the hands and feet, elevated liver enzymes, hair loss, and gastrointestinal symptoms such as nausea. These toxicities were predominantly manageable with dose modification and supportive care, and the rate of treatment discontinuation due to adverse events remained at a level consistent with clinical practice. Interstitial lung disease, the feared complication associated with some newer ADC platforms, was monitored closely and appeared uncommon in this program. The investigators note that neuropathy in particular warrants proactive monitoring in longer-term survivors.

Clinical Significance

The significance of the trial extends to its patient selection strategy. By focusing the phase 3 on unequivocally HER2 (搜索)搜索该靶点-positive disease with liver involvement, the investigators targeted the population with the highest unmet need and the clearest biological rationale. Rather than enrolling a mixed metastatic population in which liver metastases (搜索)搜索该疾病 form a small, underpowered subgroup, RC48-C006 was built from the ground up to answer whether the drug works in this specific, difficult setting—a design choice that allows the findings to be translated directly into clinical decision-making for patients whose imaging shows hepatic disease.

The results arrive at a moment of intense competition in the HER2 (搜索)搜索该靶点-directed ADC field, as drugs such as trastuzumab deruxtecan查看药品详情 have already demonstrated that payload delivery through HER2 targeting can overcome resistance to older therapies. Disitamab vedotin查看药品详情's contribution is to extend that paradigm with a distinct antibody, linker and payload combination, and to validate it in a population where head-to-head level 1 evidence has been scarce. Beyond breast cancer, the agent has been investigated in urothelial carcinoma, gastric cancer and other HER2-expressing tumors, and regulatory approvals in parts of Asia have already been based on earlier-phase evidence.

For patients and clinicians, the immediate question is sequencing: where disitamab vedotin查看药品详情 fits among trastuzumab deruxtecan查看药品详情, tucatinib combinations and other options in the expanding HER2 (搜索)搜索该靶点-positive arsenal. The investigators and independent commentators alike caution that only randomized head-to-head studies can determine optimal ordering of the newer agents. What RC48-C006 establishes is that liver metastases (搜索)搜索该疾病 need not consign patients to uniformly inferior outcomes, and that an ADC engineered with a Chinese-developed antibody, a protease-cleavable linker and a microtubule-disrupting payload can deliver clinically meaningful benefit precisely where the disease is most resistant. As follow-up matures and overall survival data accumulate, the trial is expected to serve as a reference point for the next generation of studies aimed at the metastatic sites where breast cancer still claims its greatest toll.

The study was sponsored by RemeGen Co., Ltd.查看公司主页, China, and published in Nature Communications in 2026.